Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 5Recruiting 2Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 51Lung Neoplasms 40Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 25Brain Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Pancreatic Neoplasms 21Glioma 20Breast Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 17Multiple Myeloma 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 13Carcinoma, Renal Cell 13Mouth Neoplasms 12Oropharyngeal Neoplasms 11Lymphoma, Mantle-Cell 11Carcinoma 11Triple Negative Breast Neoplasms 10Melanoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Laryngeal Neoplasms 10Ovarian Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Nasopharyngeal Carcinoma 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Hypopharyngeal Neoplasms 8Lymphoma, B-Cell 7

Interventions

Trastuzumab 3trastuzumab deruxtecan 2sacituzumab govitecan 2pertuzumab 2pembrolizumab 2Magnetic Resonance Spectroscopy 2Goserelin 2Carboplatin 2Biopsy 2Ado-Trastuzumab Emtansine 2zanidatamab 1trastuzumab biosimilar HLX02 1spartalizumab 1pyrotinib 1enfortumab vedotin 1camrelizumab 1bicalutamide 1apatinib 1abiraterone 1Tablets 1Specimen Handling 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Observation 1Maytansine 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Salivary Gland Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT05408845 2026-05-04

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NRG Oncology

Phase 2 Recruiting
146 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡